Cargando…

Reduction of malaria prevalence after introduction of artemisinin-combination-therapy in Mbeya Region, Tanzania: results from a cohort study with 6773 participants

BACKGROUND: A marked decline in malaria morbidity and mortality has been reported after the introduction of artemisinin-based combination therapy (ACT) in high malaria prevalence countries in Africa. Data on the impact of ACT and on the prevalence of malaria has so far been scarce for Southwest Tanz...

Descripción completa

Detalles Bibliográficos
Autores principales: Froeschl, Guenter, Saathoff, Elmar, Kroidl, Inge, Berens-Riha, Nicole, Clowes, Petra, Maboko, Leonard, Assisya, Weston, Mwalongo, Wolfram, Gerhardt, Martina, Ntinginya, Elias Nyanda, Hoelscher, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019526/
https://www.ncbi.nlm.nih.gov/pubmed/29940968
http://dx.doi.org/10.1186/s12936-018-2389-z
_version_ 1783335143237222400
author Froeschl, Guenter
Saathoff, Elmar
Kroidl, Inge
Berens-Riha, Nicole
Clowes, Petra
Maboko, Leonard
Assisya, Weston
Mwalongo, Wolfram
Gerhardt, Martina
Ntinginya, Elias Nyanda
Hoelscher, Michael
author_facet Froeschl, Guenter
Saathoff, Elmar
Kroidl, Inge
Berens-Riha, Nicole
Clowes, Petra
Maboko, Leonard
Assisya, Weston
Mwalongo, Wolfram
Gerhardt, Martina
Ntinginya, Elias Nyanda
Hoelscher, Michael
author_sort Froeschl, Guenter
collection PubMed
description BACKGROUND: A marked decline in malaria morbidity and mortality has been reported after the introduction of artemisinin-based combination therapy (ACT) in high malaria prevalence countries in Africa. Data on the impact of ACT and on the prevalence of malaria has so far been scarce for Southwest Tanzania. METHODS: Between 2005 and 2011, a large general population cohort in the Mbeya Region in the south-west of Tanzania has been surveyed within the EMINI-study (Evaluation and Monitoring of the Impact of New Interventions). Participants were examined once per year, including rapid diagnostic testing for malaria. ACT was introduced in the region according to national guidelines in the time period 2006/2007, replacing sulfadoxine/pyrimethamine as first-line therapy. In four study sites, 6773 individuals who participated in the first two of three consecutive survey visits in the period from 2006 to 2009 were included in this analysis. The prevalence of Plasmodium infection prior to and after the introduction of ACT was compared by logistic regression, with consideration of climatic variability, age, sex, socio-economic status and bed net use as potential confounders. RESULTS: A significant reduction over time in the prevalence of Plasmodium falciparum infection from 2.5 to 0.3% was shown across the four study sites. The decline was not explained by other factors included in the analysis, therefore, the decline over time most likely reflects the impact of introduction of ACT in the study area. CONCLUSIONS: The longitudinal study showed a significant and relevant decline in the prevalence of P. falciparum infection after introduction of ACT, which could not be explained by potential confounders. The data suggests that artemisinin-based combinations are not only an effective instrument for reduction of immediate morbidity and mortality, but also for reduction of transmission rates.
format Online
Article
Text
id pubmed-6019526
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60195262018-07-06 Reduction of malaria prevalence after introduction of artemisinin-combination-therapy in Mbeya Region, Tanzania: results from a cohort study with 6773 participants Froeschl, Guenter Saathoff, Elmar Kroidl, Inge Berens-Riha, Nicole Clowes, Petra Maboko, Leonard Assisya, Weston Mwalongo, Wolfram Gerhardt, Martina Ntinginya, Elias Nyanda Hoelscher, Michael Malar J Research BACKGROUND: A marked decline in malaria morbidity and mortality has been reported after the introduction of artemisinin-based combination therapy (ACT) in high malaria prevalence countries in Africa. Data on the impact of ACT and on the prevalence of malaria has so far been scarce for Southwest Tanzania. METHODS: Between 2005 and 2011, a large general population cohort in the Mbeya Region in the south-west of Tanzania has been surveyed within the EMINI-study (Evaluation and Monitoring of the Impact of New Interventions). Participants were examined once per year, including rapid diagnostic testing for malaria. ACT was introduced in the region according to national guidelines in the time period 2006/2007, replacing sulfadoxine/pyrimethamine as first-line therapy. In four study sites, 6773 individuals who participated in the first two of three consecutive survey visits in the period from 2006 to 2009 were included in this analysis. The prevalence of Plasmodium infection prior to and after the introduction of ACT was compared by logistic regression, with consideration of climatic variability, age, sex, socio-economic status and bed net use as potential confounders. RESULTS: A significant reduction over time in the prevalence of Plasmodium falciparum infection from 2.5 to 0.3% was shown across the four study sites. The decline was not explained by other factors included in the analysis, therefore, the decline over time most likely reflects the impact of introduction of ACT in the study area. CONCLUSIONS: The longitudinal study showed a significant and relevant decline in the prevalence of P. falciparum infection after introduction of ACT, which could not be explained by potential confounders. The data suggests that artemisinin-based combinations are not only an effective instrument for reduction of immediate morbidity and mortality, but also for reduction of transmission rates. BioMed Central 2018-06-26 /pmc/articles/PMC6019526/ /pubmed/29940968 http://dx.doi.org/10.1186/s12936-018-2389-z Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Froeschl, Guenter
Saathoff, Elmar
Kroidl, Inge
Berens-Riha, Nicole
Clowes, Petra
Maboko, Leonard
Assisya, Weston
Mwalongo, Wolfram
Gerhardt, Martina
Ntinginya, Elias Nyanda
Hoelscher, Michael
Reduction of malaria prevalence after introduction of artemisinin-combination-therapy in Mbeya Region, Tanzania: results from a cohort study with 6773 participants
title Reduction of malaria prevalence after introduction of artemisinin-combination-therapy in Mbeya Region, Tanzania: results from a cohort study with 6773 participants
title_full Reduction of malaria prevalence after introduction of artemisinin-combination-therapy in Mbeya Region, Tanzania: results from a cohort study with 6773 participants
title_fullStr Reduction of malaria prevalence after introduction of artemisinin-combination-therapy in Mbeya Region, Tanzania: results from a cohort study with 6773 participants
title_full_unstemmed Reduction of malaria prevalence after introduction of artemisinin-combination-therapy in Mbeya Region, Tanzania: results from a cohort study with 6773 participants
title_short Reduction of malaria prevalence after introduction of artemisinin-combination-therapy in Mbeya Region, Tanzania: results from a cohort study with 6773 participants
title_sort reduction of malaria prevalence after introduction of artemisinin-combination-therapy in mbeya region, tanzania: results from a cohort study with 6773 participants
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019526/
https://www.ncbi.nlm.nih.gov/pubmed/29940968
http://dx.doi.org/10.1186/s12936-018-2389-z
work_keys_str_mv AT froeschlguenter reductionofmalariaprevalenceafterintroductionofartemisinincombinationtherapyinmbeyaregiontanzaniaresultsfromacohortstudywith6773participants
AT saathoffelmar reductionofmalariaprevalenceafterintroductionofartemisinincombinationtherapyinmbeyaregiontanzaniaresultsfromacohortstudywith6773participants
AT kroidlinge reductionofmalariaprevalenceafterintroductionofartemisinincombinationtherapyinmbeyaregiontanzaniaresultsfromacohortstudywith6773participants
AT berensrihanicole reductionofmalariaprevalenceafterintroductionofartemisinincombinationtherapyinmbeyaregiontanzaniaresultsfromacohortstudywith6773participants
AT clowespetra reductionofmalariaprevalenceafterintroductionofartemisinincombinationtherapyinmbeyaregiontanzaniaresultsfromacohortstudywith6773participants
AT mabokoleonard reductionofmalariaprevalenceafterintroductionofartemisinincombinationtherapyinmbeyaregiontanzaniaresultsfromacohortstudywith6773participants
AT assisyaweston reductionofmalariaprevalenceafterintroductionofartemisinincombinationtherapyinmbeyaregiontanzaniaresultsfromacohortstudywith6773participants
AT mwalongowolfram reductionofmalariaprevalenceafterintroductionofartemisinincombinationtherapyinmbeyaregiontanzaniaresultsfromacohortstudywith6773participants
AT gerhardtmartina reductionofmalariaprevalenceafterintroductionofartemisinincombinationtherapyinmbeyaregiontanzaniaresultsfromacohortstudywith6773participants
AT ntinginyaeliasnyanda reductionofmalariaprevalenceafterintroductionofartemisinincombinationtherapyinmbeyaregiontanzaniaresultsfromacohortstudywith6773participants
AT hoelschermichael reductionofmalariaprevalenceafterintroductionofartemisinincombinationtherapyinmbeyaregiontanzaniaresultsfromacohortstudywith6773participants